Table 1:

Description of patients with new-onset hyperglycemia after starting immune checkpoint inhibitors

Age at ICI initiation	Malignancy type and stage	ICI	Weeks after initial treatment HG occurred	Peak glucose Mg/dL (mmol/L)	Setting of HG	Admission diagnosis	Hyperglycemia course
70	Colorectal cancer stage IV	Nivolumab	32	418 (23.2)	Outpatient	N/A	HG improved with basal insulin and metformin treatment
62	HCC stage IV	Nivolumab	108	230 (12.8)	Outpatient	N/A	Lost to follow up after HG
81	Melanoma stage IV	Ipilimumab	11	309 (17.1)	Inpatient and outpatient	Debility from POD	Continued intermittent HG, insulin started
57	NSCLC stage IV	Atezolizumab	18	204 (11.3)	Outpatient	N/A	No further HG without intervention
50	HCC stage IV	Nivolumab	12	277 (15.4)	Inpatient	GI bleed	Received insulin dose, then no further HG without intervention, death 2 days later
36	HCC stage IV	Nivolumab	5	250 (13.9)	Inpatient	Pneumonia and kidney injury	No further HG without intervention, death 2 days later
87	Melanoma Stage IV	Pembrolizumab	55	233 (12.9)	Outpatient	N/A	No further HG without intervention
69	Metastatic adenocarcinoma of unknown primary	Nivolumab	10	226 (12.5)	Inpatient	Dyspnea, POD	Glucose not checked after HG, death 6 days later
47	HCC stage IV	Nivolumab	9	210 (11.7)	Inpatient	Empyema	Continued HG that then resolved without intervention
59	Melanoma stage IV	Ipilimumab	4	500 (27.8)	Emergency Department	Migraine	Lost to follow-up after HG

GI= gastrointestinal; HCC= hepatocellular carcinoma; HG= hyperglycemia; ICI= immune checkpoint inhibitor; N/A= not applicable; NSCLC= non-small cell lung cancer; POD= progression of disease